title: Pretreatment tumor prostaglandin E2 concentration and cyclooxygenase-2 expression are not associated with the response of canine naturally occurring invasive urinary bladder cancer to cyclooxygenase inhibitor therapy.
abstract: The purpose of this study was to determine the extent to which pretreatment prostaglandin E2 (PGE2) concentration and cyclooxygenase-2 (cox-2) expression could be used to predict the antitumor activity of cox inhibitor treatment in naturally occurring canine transitional cell carcinoma of the urinary bladder (TCC). Snap frozen tissues (to measure PGE2) and formalin-fixed TCC samples (for cox-2 immunohistochemistry) were obtained by cystoscopy or surgery. Complete tumor staging was performed before and after one month of treatment with the cox inhibitor, piroxicam (0.3 mg/kg q24 h po). The pretreatment PGE2 concentration ranged from 57 to 1624 ng/g of TCC tissue; n=18 dogs). Cox-2 immunoreactivity was observed in all TCC samples. There was no association between PGE2 concentration, cox-2 expression, and change in tumor volume with piroxicam treatment. In conclusion, cox-2 expression or PGE2 concentration alone, or the combination of the two was not useful in predicting response to piroxicam treatment in canine TCC.
authors.affiliation: Department of Veterinary Clinical Sciences, Purdue University, Lynn Hall of Veterinary Medicine, 625 Harrison St., West Lafayette, IN 47907-2026, USA.
authors.forename: A J
authors.initials: AJ
authors.lastname: Mutsaers
authors.forename: S I
authors.initials: SI
authors.lastname: Mohammed
authors.forename: D B
authors.initials: DB
authors.lastname: DeNicola
authors.forename: P W
authors.initials: PW
authors.lastname: Snyder
authors.forename: N W
authors.initials: NW
authors.lastname: Glickman
authors.forename: P F
authors.initials: PF
authors.lastname: Bennett
authors.forename: A E
authors.initials: AE
authors.lastname: de Gortari
authors.forename: P L
authors.initials: PL
authors.lastname: Bonney
authors.forename: D W
authors.initials: DW
authors.lastname: Knapp
mesh_terms: D000818:Animals; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy / Q000201:enzymology / Q000378:metabolism*; D051546:Cyclooxygenase 2 / Q000096:biosynthesis*; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use; D015232:Dinoprostone / Q000378:metabolism*; D004285:Dogs; D007150:Immunohistochemistry; D010894:Piroxicam / Q000627:therapeutic use*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000201:enzymology*
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D010894:Piroxicam; D051546:Cyclooxygenase 2; D015232:Dinoprostone